Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02252523
Other study ID # CHU-210
Secondary ID 2013-004697-10
Status Recruiting
Phase Phase 2
First received September 26, 2014
Last updated September 26, 2014
Start date April 2014
Est. completion date April 2015

Study information

Verified date September 2014
Source University Hospital, Clermont-Ferrand
Contact Patrick LACARIN
Phone 04 73 75 11 95
Email placarin@chu-clermontferrand.fr
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

This will be an open, prospective pilot study with pharmacological analysis. This study is designed to assess the efficacity and safety of dexmedetomidine-based sedation in two subgroups of neurocritically ill patients requiring mechanical ventilation for more than 48 hours. Those with or at risk for intracranial hypertension requiring deep sedation and those requiring a light to moderate sedation for early neurological evaluation.

The main objective is to assess the feasability of dexmedetomidine infusion in terms of efficacy and safety (especially cardiovascular tolerance) in brain-injured patients admitted to intensive care unit and requiring sedation and mechanical ventilation for a predictable duration greater than or equal to 48 hours. Secondary objectives include the study of hemodynamic parameters evolution, dose-response relationship, blood (+/- cerebrospinal fluid) drug concentration, opioates and co-hypnotic consumption.


Description:

A written informed consent will be obtained from patients next-of-kin, before study enrollment according to inclusion and exclusion criterias. All consecutive brain-injured patients (traumatic brain injury, subarachnoid or intracerebral hemorrhage, postoperative neurosurgical procedure) admitted to our neurocritical care unit, older than 18 years and requiring sedation and analgesia for mechanical ventilation longer than 48 hours, will be eligible for the study. Depending on the absence or presence of lesion which may increase intracranial pressure, patients will be included in the "light to moderate" sedation subgroup (MLS) or in the "deep" sedation subgroup (DS).

In the MLS subgroup (RASS 0/-3), sedation and analgesia will be drived by propofol and opiates. Once the goals of sedation achieved with usual hypnotic, dexmedetomidine will be initiated at a dose of 0.5 μg/kg/h, and then gradually increased or decreased by increments of 0.1 μ g / kg / h all hours to a maximum dose of 1.4 μg/kg/h, depending on the target sedation achievement. Propofol will be discontinued at study drug initiation. Dexmedetomidine infusion will bemaintained at least during 48 hours, evaluation of the efficacy and safety will be continuous during this period.

After these first 48 hours, in the absence of neurological worsening requiring a deep sedation and if sedation's levels will are achieved with dexmedetomidine alone (ie without requirement of propofol continuous administration) , it will be maintained untill withdrawal of mechanical ventilation. Otherwise, study drug will discontinued and propofol will be restarted.

In the DS subgroup, "deep" sedation (RASS -4/-5) will be achieved by propofol infusion. If sedation level are not achieved with the maximum recommended propofol dose (5mg/kg/h), midazolam will be started to reach target sedation level with a maximum dose of 0.15mg/kg/h. Once the goals of sedation will be achieved a dexmedetomidine infusion will be initiated at a dose of 0.5 μg/kg/h and then gradually titrated by increase of 0.1 μg/kg/h every hour up to the maximum patient-tolerated dose (maximum dose of 1.4 μg/kg/h). Conventional hypnotic doses will be adjusted according to the sedation target. In parallel to dexmedetomidine titration, midazolam first and then propofol will be decreased. The study drug will be maintained at the maximum patient-tolerated dose for a total of 48 hours during which the efficacy and safety will be assessed continuously. After this period, dexmedetomidine will be discontinued. According to the patient's neurological evolution, either sedation objectives will remain identical (RASS -4/-5), or sedation will be decreased. Conventional hypnotic will be used again to achieve these objectives.

The expected result of this study is to confirm that the administration of dexmedetomidine is effective and safe for "light to moderate" and "deep" sedation of brain-injured patients admitted to intensive care unit. In addition, this feasibility study could provide legitimacy if the results are conclusive, to conduct a prospective multicenter randomized controlled trial on the potential benefits of dexmedetomidine in neurocritical ill patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 66
Est. completion date April 2015
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Brain-injured patients (traumatic brain injury, subarachnoid or intracerebral hemorrhage, postoperative neurosurgical procedure)

- Older than 18 years

- Requiring sedation and analgesia for mechanical ventilation longer than 48 hours

- Written informed consent obtained from patients next-of-kin, before study enrollment

- Depending on the absence or presence of lesion which may increase intracranial pressure, patients will be included in the "light to moderate" sedation subgroup or in the "deep" sedation subgroup

Exclusion Criteria:

- - Heart rate < 45 bpm,

- Uncontrolled shock or cardiac failure,

- High-grade AV block,

- Acute ischemic neurological injury,

- Severe liver failure,

- Drug overdose and prior enrollment in a trial with any experimental drug in the last 30 days,

- Need for ongoing neuromuscular blockade except for tracheal intubation,

- Pregnancy/lactation,

- Known allergic reaction to dexmedetomidine,

- Uncontrolled diabetes.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Dexmedetomidine


Locations

Country Name City State
France CHU Clermont-Ferrand Clermont-Ferrand

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand Orion Corporation provides financial support.

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hemodynamic events at day 1 Yes
Primary Adverse effects other than hemodynamic event at day 1 Yes
Primary Premature discontinuation of dexmedetomidine infusion at day 1 Yes
Primary Delirium assessed by CAM- ICU scale at day 1 Yes
Primary Withdrawal syndrome at dexmedetomidine discontinuation at day 1 Yes
Secondary Level of sedation assessed by the RASS scale from dexmedetomidine initation at day 1 Yes
Secondary Dose of dexmedetomidine necessary to achieve the objectives of sedation at day 1 Yes
Secondary Effective plasma concentration at day 1 Yes
See also
  Status Clinical Trial Phase
Completed NCT02974959 - Vagus Nerve Stimulation to Treat Moderate Traumatic Brain Injury Phase 1
Completed NCT01728831 - Study of Cerebral Tissue Oxygenation During Transfusion in Traumatic Brain Injury N/A
Completed NCT02786706 - Automated Measurement of Optic Nerve Sheath Diameter
Completed NCT02670733 - Effect of Increased Positive End-expiratory Pressure on Intracranial Pressure in Different Respiratory Mechanic in Acute Respiratory Distress Syndrome N/A
Suspended NCT02174016 - The Ketogenic Diet for Pediatric Acute Brain Injury N/A
Completed NCT03694678 - Recovering Together: Building Resiliency in Dyads of Patients Admitted to the Neuroscience Intensive Care Unit (NICU) and Their Caregivers N/A
Completed NCT01069250 - Dynamic and Static Autoregulation After Brain Injury N/A
Recruiting NCT02644265 - CONNECT-ME: Consciousness in Neurocritical Care Cohort Study Using fMRI and EEG
Not yet recruiting NCT03110237 - A Multidimensional Inpatient Balance Training Class to Improve Functional Outcomes in Rehabilitation Inpatients With ABI N/A